Articles, Case Studies and Resources | Acumetis

What the National Cancer Plan for England signals for oncology innovation and access

Explore how the National Cancer Plan for England is reshaping oncology access expectations, regulatory timelines, and HTA and JCA planning.

How to use early modeling to assess price potential and HTA strategy

Learn how early modeling supports pricing strategy, HTA planning, cost-effectiveness assessment, and evidence generation to strengthen market access decision-making.

Why NICE’s new cost-effectiveness threshold matters for pharmaceutical access in the UK

NICE updates its cost-effectiveness threshold. Discover the implications of this change for the UK HTA, patient access, and pricing strategy.

What Is the EU’s pharmaceutical legislation agreement telling the industry?

Overview of the EU pharmaceutical legislation agreement and its implications for the industry, from market exclusivity to regulatory reform.

Strategic competitor analysis for gene therapy markets

Explore how gene therapy competitor analysis supports market entry strategy, competitive intelligence, market access planning, and long-term commercialization success.

Maximizing market potential with target patient population analysis

Explore how our team curated a target patient population analysis supporting pediatric and adult commercialization strategy, market assessment, and long-term growth planning.

The “direct” continuum: Decoding direct-to-patient and direct-to-employer for commercial success

Explore how DTP and DTE models are reshaping commercialization, improving patient access, affordability, engagement, and market strategy.

How strategic market access insights strengthen coverage and accelerate access

Explore how the Acumetis Advisor Network delivers real-world perspectives from payers, PBMs, IDNs, and global access leaders to support stronger market access strategy and decision making.

Strategic launch in a rare hematologic disease

Explore how Acumetis supported launch readiness for a novel rare hematologic disease therapy through scientific positioning, stakeholder engagement, KOL insights, and cross-functional Medical Affairs strategy.